SAPIEN M3 System TransCatheter MItral Valve ReplaCement via TransseptaL AccEss
To establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable due to clinical, anatomic or technical considerations.
Primary Investigator: Santiago Garcia